Author: Nicola F Fletcher; Luke W Meredith; Emma L Tidswell; Steven R Bryden; Daniel Gonçalves-Carneiro; Yasmin Chaudhry; Claire Shannon-Lowe; Michael A Folan; Daniella A Lefteri; Marieke Pingen; Dalan Bailey; Clive S McKimmie; Alan W Baird
Title: A novel antiviral formulation inhibits a range of enveloped viruses. Document date: 2020_3_30
ID: nly9vojr_74
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10. 1101 /2020 The ViroSAL used in these studies is a proprietary emulsion of free fatty acids that has previously been shown to have antibacterial properties, including against a range of veterinary periodontopathogens (Laverty et al., 2015) , Staphylococcus species including methicillin-resistant Staphylococcus aureus (Hogan et al., 2016) as well as a wide.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10. 1101 /2020 The ViroSAL used in these studies is a proprietary emulsion of free fatty acids that has previously been shown to have antibacterial properties, including against a range of veterinary periodontopathogens (Laverty et al., 2015) , Staphylococcus species including methicillin-resistant Staphylococcus aureus (Hogan et al., 2016) as well as a wide range of culturable species from human colon (McDermott et al., 2015) . The antimicrobial activity of medium chain saturated and long chain unsaturated free fatty acids has been reported previously (Thormar and Hilmarsson, 2007) , with both antibacterial and antiviral activity observed (Hilmarsson et al., 2005) .
Search related documents:
Co phrase search for related documents- antimicrobial activity and fatty acid: 1, 2, 3, 4, 5
- antimicrobial activity and human colon: 1, 2, 3, 4
- antimicrobial activity and medium chain: 1
- antimicrobial activity and methicillin resistant Staphylococcus aureus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- antimicrobial activity and previously report: 1, 2
- antimicrobial activity and Staphylococcus aureus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- antimicrobial activity and wide range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antiviral antibacterial activity and Staphylococcus aureus: 1, 2
- antiviral antibacterial activity and wide range: 1, 2
- fatty acid and free fatty acid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- fatty acid and medium chain: 1, 2, 3, 4, 5, 6, 7, 8
- fatty acid and methicillin resistant Staphylococcus aureus: 1
- fatty acid and Staphylococcus aureus: 1, 2, 3, 4, 5
- fatty acid and wide range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- human colon and methicillin resistant Staphylococcus aureus: 1
- human colon and Staphylococcus aureus: 1, 2
- human colon and wide range: 1, 2
- medium chain and proprietary emulsion: 1, 2
- medium chain and wide range: 1, 2
Co phrase search for related documents, hyperlinks ordered by date